Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00825565 · ClinicalTrials.gov registry record · Phase 2
Study of Alwextin® Cream in Treating Epidermolysis Bullosa
A Phase 2 study of Epidermolysis Bullosa, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00825565: Completed Phase 2 study of Epidermolysis Bullosa, sponsored by Northwestern University.
NCT00825565 is a Phase 2 study of Epidermolysis Bullosa that has completed, run by Northwestern University. The registered enrollment target is 8 participants, below the 19-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00825565, a Phase 2 study of Epidermolysis Bullosa, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine how safe and effective allantoin 3% cream (Alwextin) is in improving the healing of recurrent skin lesions and reducing overall blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically to the entire body once daily.
Primary Outcome
A common measure of the degree of involvement in skin disease is the Body Surface Area Index (BSAI). This measure is also commonly used in psoriasis studies. It is a global measure of disease "spread" with weighting factors.
Conditions Studied
Interventions
- DRUG Alwextin cream
Study Locations (1)
Illinois
- Robert and Ann Lurie Children's Hospital of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT00825565 record still lists
NCT00825565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 19-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Epidermolysis Bullosa appearing as the primary indexed condition, and to 1 intervention - of which Alwextin cream is the first listed.
NCT00825565 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00825565 about?
NCT00825565 is a clinical study titled "Study of Alwextin® Cream in Treating Epidermolysis Bullosa". The purpose of this study is to determine how safe and effective allantoin 3% cream (Alwextin) is in improving the healing of recurrent skin lesions and reducing overall blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically to the entire body once daily.
What is the current status of trial NCT00825565?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2009-02. Estimated completion is 2010-11.
What conditions does trial NCT00825565 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa.
What interventions are being tested in trial NCT00825565?
The interventions under investigation include: Alwextin cream (DRUG).
Who is sponsoring clinical trial NCT00825565?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00825565 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00825565's enrollment target sits among peer trials
8 10th of 10 the lowest of 10 other Epidermolysis Bullosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epidermolysis Bullosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
COMPLETED · Phase 2
-
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
COMPLETED · Phase 2
-
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
COMPLETED · Phase 2
-
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
ACTIVE NOT RECRUITING · Phase 3
-
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia